2. Academic Validation
  3. Phenoxymethyl 1,3-oxazoles and 1,2,4-oxadiazoles as potent and selective agonists of free fatty acid receptor 1 (GPR40)

Phenoxymethyl 1,3-oxazoles and 1,2,4-oxadiazoles as potent and selective agonists of free fatty acid receptor 1 (GPR40)

  • Bioorg Med Chem Lett. 2015 Aug 15;25(16):3105-11. doi: 10.1016/j.bmcl.2015.06.018.
Ihor Zahanich 1,  Ivan Kondratov 2,  Vasyl Naumchyk 3,  Yuri Kheylik 1,  Maxim Platonov 1,  Sergey Zozulya 3,  Mikhail Krasavin 4
Affiliations

Affiliations

  • 1 Enamine Ltd, 78 Chervonotkatska, Kyiv 02094, Ukraine.
  • 2 Enamine Ltd, 78 Chervonotkatska, Kyiv 02094, Ukraine; Institute of Bioorganic Chemistry and Petrochemistry, National Ukrainian Academy of Science, 1 Murmanska, Kyiv 02660, Ukraine.
  • 3 Enamine Ltd, 78 Chervonotkatska, Kyiv 02094, Ukraine; Taras Shevchenko National University, 62 Volodymyrska, Kyiv 01033, Ukraine.
  • 4 Institute of Chemistry, St. Petersburg State University, 26 Universitetskyi Prospekt, Peterhof 198504, Russian Federation. Electronic address: [email protected].
PMID: 26096679 DOI: 10.1016/j.bmcl.2015.06.018
Abstract

A screening hit that showed a weak (EC50 = 18 μM), partial agonistic effect on GPR40 was used a prototype for expedited hit expansion effort using a set of advanced building blocks. The latter yielded several 1,3-oxazoles and 1,2,4-oxadiazoles with significantly improved potency (best EC50 = 0.058 μM). The lead compounds in each chemotype showed a very good ADME profile (aqueous solubility, plasma protein binding, microsomal stability and membrane permeability) and no appreciable inhibition of key cytochromes P450. The compounds reported are significant new starting points for further preclinical development of future diabetic agents with a mechanism of action for which a first-in-class agent is yet to be approved.

Keywords

ADME profile; Agonists; Anti-diabetic agents; Cytochrome inhibition; Free fatty acid receptor agonists; Glucose-stimulated insulin secretion; Hit expansion; Hypoglycemia.

Figures
Products